Skip to main content
    L

    LeMaitre Vascular Inc (LMAT)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $77.01
    -1.28 (-1.63%)

    Market Cap: $1.79B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    LeMaitre Vascular Inc (LMAT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    LeMaitre Vascular reported revenue of $249.60M for the fiscal year ended Dec 31, 2025, up 13.5% from the year before. That year, net income was $57.73M with a net margin of 23.1%, operating cash flow was $81.25M and free cash flow was $74.47M. The quarter ended Sep 30, 2026 had revenue of $67.97M and net income of $15.02M.

    Revenue and Margins

    The operating margin was 27.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $89.15M, a compound annual rate of 12.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$249.60M+13.5%71.5%27.2%23.1%
    Dec 2024$219.86M+13.6%68.6%23.8%20.0%
    Dec 2023$193.48M+19.7%65.7%19.0%15.6%
    Dec 2022$161.65M+4.7%64.9%16.6%12.8%
    Dec 2021$154.42M+19.4%65.7%23.6%17.4%
    Dec 2020$129.37M+10.4%65.4%22.3%16.4%
    Dec 2019$117.23M+11.0%68.1%18.1%15.3%
    Dec 2018$105.57M+4.7%70.0%26.7%21.7%
    Dec 2017$100.87M+13.1%70.1%20.9%17.0%
    Dec 2016$89.15MN/A70.6%18.3%11.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 31.1% from the year before. In the quarter ended Sep 2026, net income fell 13.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$249.60M$219.86M$193.48M$161.65M$154.42M$129.37M$117.23M$105.57M$100.87M$89.15M
    Cost of revenue$71.06M$68.96M$66.44M$56.76M$53.04M$44.75M$37.38M$31.63M$30.17M$26.21M
    Gross profit$178.54M$150.90M$127.05M$104.90M$101.38M$84.62M$79.85M$73.94M$70.70M$62.94M
    Research and development$14.14M$15.65M$16.97M$13.29M$11.80M$10.10M$9.28M$8.20M$6.64M$6.14M
    Operating income$67.91M$52.26M$36.71M$26.83M$36.42M$28.79M$21.18M$28.21M$21.10M$16.34M
    Net income$57.73M$44.04M$30.11M$20.64M$26.91M$21.22M$17.93M$22.94M$17.18M$10.59M
    EBITDA$78.56M$61.80M$45.91M$35.94M$47.38M$36.85M$26.40M$32.14M$25.00M$19.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$67.97M$70.38M$66.55M$64.45M$61.05M$64.23M$59.87M$55.72M$54.82M$55.85M$53.48M$48.88M
    Gross profit$48.70M$50.76M$48.40M$46.19M$45.95M$44.97M$41.42M$38.59M$37.18M$38.47M$36.66M$33.27M
    Operating income$17.70M$20.40M$17.77M$18.83M$20.31M$16.14M$12.63M$12.85M$13.15M$14.38M$11.87M$10.21M
    Net income$15.02M$17.05M$15.68M$15.58M$17.36M$13.78M$11.01M$11.18M$11.14M$11.83M$9.89M$8.46M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $171.59M exceeded cash and equivalents by $143.34M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$615.69M$551.82M$346.78M$310.48M$292.80M$252.81M$188.34M$153.09M$126.32M$101.92M
    Current assets$468.23M$402.19M$194.60M$161.73M$139.88M$94.26M$92.09M$94.02M$80.31M$59.03M
    Cash and equivalents$28.24M$25.61M$24.27M$19.13M$13.86M$26.76M$11.79M$26.32M$19.10M$24.29M
    Total liabilities$222.17M$214.53M$48.88M$42.27M$38.65M$80.24M$40.20M$22.85M$16.55M$14.42M
    Short-term debt$2.94M$2.68M$2.47M$1.89M$1.87M$2.50M$0$2.93MN/AN/A
    Long-term debt$168.65M$167.77M$0N/AN/A$35.53M$0N/A$0$0
    Shareholder equity$393.52M$337.29M$297.90M$268.20M$254.15M$172.57M$148.14M$130.24M$109.77M$87.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$656.03M$640.55M$629.53M$615.69M$598.07M$577.59M$556.01M$551.82M$377.02M$363.08M$353.96M$346.78M
    Total liabilities$223.90M$220.21M$222.90M$222.17M$219.15M$214.91M$208.43M$214.53M$45.95M$43.55M$45.45M$48.88M
    Cash and equivalents$27.49M$26.63M$26.85M$28.24M$25.49M$27.18M$25.34M$25.61M$21.00M$22.27M$26.59M$24.27M
    Shareholder equity$432.13M$420.34M$406.62M$393.52M$378.92M$362.69M$347.57M$337.29M$331.07M$319.53M$308.50M$297.90M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 91.7% of operating cash flow. Dividends and share repurchases together came to 26.8% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$81.25M$44.12M$36.75M$25.38M$35.10M$34.80M$14.18M$19.51M$22.87M$16.90M
    Capital expenditures$6.78M$6.96M$7.26M$3.23M$4.88M$2.98M$3.76M$3.05M$6.42M$2.84M
    Free cash flow$74.47M$37.16M$29.49M$22.15M$30.22M$31.82M$10.42M$16.45M$16.45M$14.05M
    Dividends paid$18.11M$14.38M$12.45M$10.99M$9.34M$7.70M$6.74M$5.45M$4.18M$3.32M
    Share repurchases$1.82M$1.72M$853.00K$642.00K$802.00K$570.00K$683.00K$741.00K$778.00K$311.00K
    Investing cash flow-$64.94M-$200.12M-$24.71M-$10.37M-$61.08M-$52.89M-$24.10M-$7.05M-$28.96M-$17.21M
    Financing cash flow-$14.54M$158.10M-$7.13M-$9.23M$13.70M$32.16M-$4.62M-$4.42M$80.00K-$2.58M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$21.99M$15.96M$15.09M$23.16M$28.76M$20.29M$9.04M$15.18M$14.25M$9.63M$5.07M$10.75M
    Capital expenditures$2.33M$2.31M$2.78M$1.78M$2.28M$1.34M$1.38M$2.04M$1.67M$1.88M$1.37M$1.28M
    Free cash flow$19.66M$13.65M$12.31M$21.38M$26.48M$18.95M$7.66M$13.14M$12.58M$7.75M$3.70M$9.47M
    Last 12 quarters

    Frequently Asked Questions About LMAT

    What is LeMaitre Vascular's annual revenue?

    LeMaitre Vascular reported revenue of $249.60M for the fiscal year ended Dec 31, 2025.

    How fast is LeMaitre Vascular's revenue growing?

    Revenue was up 13.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 15.6%.

    Is LeMaitre Vascular profitable?

    Yes. LeMaitre Vascular reported net income of $57.73M for the fiscal year ended Dec 31, 2025, with a net margin of 23.1%.

    How much free cash flow does LMAT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $81.25M minus capital expenditures of $6.78M produced free cash flow of $74.47M.

    How much debt does LeMaitre Vascular have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $168.65M, short-term debt of $2.94M and cash and equivalents of $28.24M.